



IFW 1614

ANGES-5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group Art Unit : 1614
Applicants : Yoshiki Sawa et al.
Application No. : 10/509,799
Confirmation No. : 3108
371(c) Date : July 15, 2005
For : DECOY COMPOSITION FOR TREATMENT AND
PREVENTION OF BRAIN DISEASE AND DISORDERS

New York, New York
June 26, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT


Sir:

Transmitted herewith is a Supplemental Information Disclosure Statement, a completed Form PTO/SB/08A and copies of the documents cited therein in the above-identified application.

This Statement is submitted more than three months from the application filing date, but before the mailing of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97 (b)(3), no fee is due in connection with this Statement. However, if

for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Statement to Deposit Account No. 06-1075, Order No. 003734-0055. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,




Margaret A. Pierri (Reg. No. 30,709)

Attorney for Applicants

c/o FISH & NEAVE IP GROUP
ROPES & GRAY LLP
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax.: (212) 596-9090

I hereby certify that this correspondence
is being deposited with the US Postal Service
as First Class Mail in an envelope Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

June 26, 2006

Signature of person Signing



ANGES-5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group Art Unit : 1614
Applicants : Yoshiki Sawa et al.
Application No. : 10/509,799
Confirmation No. : 3108
371(c) Date : July 15, 2005
For : DECOY COMPOSITION FOR TREATMENT AND
PREVENTION OF BRAIN DISEASE AND DISORDERS

New York, New York
June 26, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make of record
the following documents, copies of which are submitted herewith.*

* For the Examiner's convenience, applicants have also enclosed a completed Form
PTO/SB/08A, listing these documents.

Articles

Altschul et al., "Basic local alignment search tool," *Journal of Molecular Biology*, 215:403-410 (1990).

Aoki et al., "Effects of cerebroplegic solutions during hypothermic circulatory arrest and short-term recovery," *Journal of Thoracic and Cardiovascular Surgery*, 108:291-301 (1994).

Ardailou et al., "Production et activite proinflammatoire de necrose tumorale alpha dans le glomerule," *Bulletin de l'Academie Nationale de Medecine*, 179:103-116 (1995).

Attiga et al., "Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases," *Cancer Research*, 60:4629-4637 (2000).

Baeuerle et al., "Function and activation of NF- κ B in the immune system," *Annual Review of Immunology*, 12:141-179 (1994).

Baker et al., "Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging," *British Journal of Surgery*, 87: 1215-1221 (2000).

Bellinger et al., "Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass," *New England Journal of Medicine*, 332:549-555 (1995).

Bond et al., "Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B," *FEBS Letters*, 435(1):29-34 (1998).

Bond et al., "Nuclear factor κ B activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts," *Biochemical and Biophysical Research Communications*, 264:561-567 (1999).

Brunner et al., "Single bilayer vesicles prepared without sonication physico-chemical properties," *Biochimica et Biophysica Acta*, 455:322-331 (1976).

Cheng et al., "Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury," *Journal of Clinical Investigation*, 101:1992-1999 (1998).

Christman et al., "Nuclear factor κ B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy," *Intensive Care Medicine* 24:1131-1138 (1998).

Clemens et al., "Global cerebral ischemia activates nuclear factor- κ B prior to evidence of DNA fragmentation," *Molecular Brain Research*, 48:187-196 (1997).

Cooper et al., "Myocardial nuclear factor- κ B activity and nitric oxide production in rejecting cardiac allografts," *Transplantation*, 66(7):838-844 (1998).

Deamer, "Preparation and properties of ether-injection liposomes," *Annals of the New York Academy of Sciences*, 308:250-258 (1978).

Denhardt, "Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy," *Critical Reviews in Oncogenesis*, 7(3&4):261-291 (1996).

Depre et al., "Unloaded heart *in vivo* replicates fetal gene expression of cardiac hypertrophy," *Nature Medicine*, 4(11):1269-1275 (1998).

Eberhardt et al., "Amplification of IL-1 β -induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF- κ B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways," *Journal of Immunology*, 165:5788-5797 (2000).

Farias et al., "Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients," *International Journal of Cancer*, 89:389-394 (2000).

Gaetani et al., "Metalloproteases and intracranial vascular lesions," *Neurological Research*, 21:385-390 (1999).

Grilli et al., "Neuroprotection by aspirin and sodium salicylate through blockade of NF- κ B activation," *Science*, 274:1383-1385 (1996).

Hagihara et al., "Widespread gene transfection into the central nervous system of primates," *Gene Therapy*, 7:759-763 (2000).

Horikawa et al., "Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma," *Cancer*, 89:715-723 (2000).

Howard et al., "NF- κ B is activated and ICAM-1 gene expression is upregulated during reoxygenation of human brain endothelial cells," *Neuroscience Letters*, 248:199-203 (1998).

Ikeda et al., "Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film *in situ* zymography," *Clinical Cancer Research*, 6:3290-3296 (2000).

Jia et al., "Suppression of human microvascular endothelial cell invasion and morphogenesis with synthetic matrixin inhibitors. Targeting angiogenesis with MMP inhibitors," *Advances in Experimental Medicine and Biology*, 476: 181-194 (2002).

Jonas, "Hypothermia, circulatory arrest, and the pediatric brain," *Journal of Cardiothoracic and Vascular Anesthesia*, 10:66-74 (1996).

Kanda et al., "The role of the activated form of matrix metalloproteinase-2 in urothelial cancer," *BJU International*, 86:553-557 (2000).

- Kim et al., "Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF- κ B-dependent pathway," *Biochemical and Biophysical Research Communications*, 269:401-405 (2000).
- Kirino, "Delayed neuronal death in the gerbil hippocampus following ischemia," *Brain Research*, 239:57-69 (1982).
- Kirklin et al., "The damaging effects of total circulatory arrest during hypothermia," *Cardiac Surgery*, 1:66-73 (1993).
- Kuner et al., " β -amyloid binds to p75^{NTR} and activates NF κ B in human neuroblastoma cells," *Journal of Neuroscience Research*, 54:798-804 (1998).
- Kurth et al., "Regional patterns of neuronal death after deep hypothermic circulatory arrest in newborn pigs," *Journal of Thoracic Cardiovascular Surgery*, 118:1068-1077 (1999).
- La Rosa et al., "Differential regulation of the c-myc oncogene promoter by the NF- κ B rel family of transcription factors," *Molecular and Cellular Biology*, 14(2):1039-1044 (1994).
- Lenardo et al., "NF- κ B: A pleiotropic mediator of inducible and tissue-specific gene control," *Cell*, 58:227-229 (1989).
- Libermann et al., "Activation of interleukin-6 gene expression through NF- κ B transcription factor," *Molecular and Cellular Biology*, 10(5):2327-2334 (1990).
- Lin et al., "Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade," *Biochemical Pharmacology*, 58:911-915 (1999).
- Mann et al., "Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial," *Lancet*, 354:1493-1498 (1999).
- Marti HP, "New strategy to treat glomerular inflammation by inhibition of mesangial cell matrix metalloproteinases," *Schweiz Med Wochenschr*, 130(21): 784-788 (2000).
- Morishita et al., "A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo," *Proceedings of the National Academy of Sciences of the United States of America*, 92:5855-5859 (1995).
- Morishita et al., "Novel strategy of gene therapy in cardiovascular disease with HVJ-liposome method," *Progression of Chronic Renal Diseases, Contributions to Nephrology*, 118:254-264 (1996).
- Morishita et al., "In vivo transfection of cis element "decoy" against nuclear factor- κ B binding site prevents myocardial infarction," *Nature Medicine*, 3(8):894-899 (1997).
- Neish et al., "Function analysis of the human vascular cell adhesion molecule 1 promoter," *Journal of Experimental Medicine*, 176:1583-1593 (1992).

Ono et al., "Decoy administration of NF-kappaB into the subarachnoid space for cerebral angiopathy," *Human Gene Therapy*, 9(7):1003-1011 (1998). Erratum in: *Human Gene Therapy* 10(2):335 (1999).

Pellegrini et al., "Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer," *Cancer Immunology Immunotherapy*, 49:388-394 (2000).

Peters et al., "Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm," *Stroke*, 30:2612-2616 (1999).

Preston et al., "Evidence for pore-like opening of the blood-brain barrier following forebrain ischemia in rats," *Brain Research*, 761:4-10 (1997).

Rappaport et al., "Relation of seizures after cardiac surgery in early infancy to neurodevelopmental outcome," *Circulation*, 97:773-779 (1998).

Rayet et al., "Aberrant *rel/nfkb* genes and activity in human cancer," *Oncogene*, 18:6938-6947 (1999).

Reich et al., "Cardiopulmonary support and physiology," *Journal of Thoracic and Cardiovascular Surgery*, 117:156-163 (1999).

Royds et al., "Response of tumour cells to hypoxia: Role of p53 and NFκB," *Journal of Clinical Pathology: Molecular Pathology*, 51:55-61 (1998).

Sakata et al., "Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary," *International Journal of Oncology*, 17:673-681 (2000).

Satriano et al., "Activation and attenuation of transcription factor NF-κB in mouse glomerular mesangial cells in response to tumor necrosis factor-α, immunoglobulin G, and adenosine 3':5'-cyclic monophosphate," *Journal of Clinical Investigation*, 94:1629-1636 (1994).

Sawa et al., "A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFκB binding site," *Circulation*, 96(9):II-280-285 (1997).

Schneider et al., "NF-κB is activated and promotes cell death in focal cerebral ischemia," *Nature Medicine*, 5(5):554-559 (1999).

Schreck et al., "Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1," *The EMBO Journal*, 10(8):2247-2258 (1991).

Schulze-Osthoff et al., "Regulation of NF-κB activation by MAP kinase cascades," *Immunobiology*, 198:35-49 (1997).

Shin et al., "Effects of tumor necrosis factor- α and interferon- γ on expression of matrix metalloproteinase-2 and -9 in human bladder cancer cells," *Cancer Letters*, 159:127-134 (2000).

Stephenson et al., "Transcription factor nuclear factor-kappa B is activated in neurons after focal cerebral ischemia," *Journal of Cerebral Blood Flow and Metabolism*, 20:592-603 (2000).

Sullenger et al., "Analysis of *trans*-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation," *Journal of Virology*, 65(12):6811-6816 (1991).

Szoka et al., "Preparation of unilamellar liposomes of intermediate size (0.1-0.2 μ m) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes," *Biochimica et Biophysica Acta*, 601:559-571 (1980).

Tomita et al., "Transcription factor decoy for NF κ B inhibits TNF- α -induced cytokine and adhesion molecule expression in vivo," *Gene Therapy*, 7:1326-1332 (2000).

Tomita et al., "Transcription factor decoy for NF κ B inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis," *Rheumatology*, 39:749-757 (2000).

Torre et al., "Partial or global rat brain ischemia: the SCOT model," *Brain Research Bulletin*, 26:365-372 (1991).

Treharne et al., "Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease," *British Journal of Surgery*, 86:1053-1058 (1999).

Turner et al., "Role of matrix metalloproteinase 9 in pituitary tumor behavior," *Journal of Clinical Endocrinology & Metabolism*, 85(8):2931-2935 (2000).

Vanicky et al., "Alterations in MAP2 immunostainability after prolonged complete brain ischemia in the rat," *NeuroReport*, 7:161-164 (1995).

Vogt et al., "Oxidative stress and hypoxia/reoxygenation trigger CD95 (APO-1/Fas) ligand expression in microglial cells," *FEBS Letters*, 429:67-72 (1998).


Wu et al., "NF- κ B activation of p53," *Journal of Biological Chemistry*, 269(31):20067-20074 (1994).

Applicants further request that the cited documents be (1) fully considered by the Examiner during the course of examination of this application, and (2) printed on any patent issuing from this application. Additionally, applicants request that a copy of

Form PTO/SB/08A, as considered and initialed by the Examiner, be returned with the next communication.

This Statement is submitted more than three months from the application filing date, but before the mailing of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97 (b)(3), no fee is due in connection with this Statement. However, if for any reason a fee is due, the Director is hereby authorized (in the accompanying Transmittal Letter) to charge payment of any fees required in connection with this Statement to Deposit Account No. 06-1075, Order No. 003734-0055.


Respectfully submitted,

A handwritten signature in black ink, appearing to read "Margaret A. Pierri", is written over a horizontal line.

Margaret A. Pierri (Reg. No. 30,709)

Attorney for Applicants

c/o FISH & NEAVE IP GROUP
ROPES & GRAY LLP
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax.: (212) 596-9090



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO				Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/509,799
				371(c) Date	July 15, 2005
				First Named Inventor	Yoshiki Sawa et al.
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	7	Attorney Docket Number	ANGES-5

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. ¹	Include name of the author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published	T ⁴
		Altschul et al., "Basic local alignment search tool," <i>Journal of Molecular Biology</i> , 215:403-410 (1990).	
		Aoki et al., "Effects of cerebroplegic solutions during hypothermic circulatory arrest and short-term recovery," <i>Journal of Thoracic and Cardiovascular Surgery</i> , 108:291-301 (1994).	
		Ardaillou et al., "Production et activite proinflammatoire de necrose tumorale alpha dans le glomerule," <i>Bulletin de l'Academie Nationale de Medecine</i> , 179:103-116 (1995).	English summary on pg. 112-113
		Attiga et al., "Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases," <i>Cancer Research</i> , 60:4629-4637 (2000).	
		Baeuerle et al., "Function and activation of NF-κB in the immune system," <i>Annual Review of Immunology</i> , 12:141-179 (1994).	
		Baker et al., "Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging," <i>British Journal of Surgery</i> , 87: 1215-1221 (2000).	
		Bellinger et al., "Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass," <i>New England Journal of Medicine</i> , 332:549-555 (1995).	
		Bond et al., "Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B," <i>FEBS Letters</i> , 435(1):29-34 (1998).	
		Bond et al., "Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts," <i>Biochemical and Biophysical Research Communications</i> , 264:561-567 (1999).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.




Substitute for form 1449/PTO		Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/509,799
		Filing Date	July 15, 2005
		First Named Inventor	Yoshiki Sawa et al.
		Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet	2	of	7
		Attorney Docket Number	ANGES-5

NON PATENT LITERATURE DOCUMENTS			
		Brunner et al., "Single bilayer vesicles prepared without sonication physico-chemical properties," <i>Biochimica et Biophysica Acta</i> , 455:322-331 (1976).	
		Cheng et al., "Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury," <i>Journal of Clinical Investigation</i> , 101:1992-1999 (1998).	
		Christman et al., "Nuclear factor κB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy," <i>Intensive Care Medicine</i> 24:1131-1138 (1998).	
		Clemens et al., "Global cerebral ischemia activates nuclear factor-κB prior to evidence of DNA fragmentation," <i>Molecular Brain Research</i> , 48:187-196 (1997).	
		Cooper et al., "Myocardial nuclear factor-κB activity and nitric oxide production in rejecting cardiac allografts," <i>Transplantation</i> , 66(7):838-844 (1998).	
		Deamer, "Preparation and properties of ether-injection liposomes," <i>Annals of the New York Academy of Sciences</i> , 308:250-258 (1978).	
		Denhardt, "Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy," <i>Critical Reviews in Oncogenesis</i> , 7(3&4):261-291 (1996).	
		Depre et al., "Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy," <i>Nature Medicine</i> , 4(11):1269-1275 (1998).	
		Eberhardt et al., "Amplification of IL-1β-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-κB and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways," <i>Journal of Immunology</i> , 165:5788-5797 (2000).	
		Farias et al., "Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients," <i>International Journal of Cancer</i> , 89:389-394 (2000).	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if known			
		Application Number	10/509,799		
		Filing Date	July 15, 2005		
		First Named Inventor	Yoshiki Sawa et al.		
		Art Unit	1614		
		Examiner Name	Not Yet Assigned		
Sheet	3	of	7	Attorney Docket Number	ANGES-5

NON PATENT LITERATURE DOCUMENTS			
		Gaetani et al., "Metalloproteases and intracranial vascular lesions," <i>Neurological Research</i> , 21:385-390 (1999).	
		Grilli et al., "Neuroprotection by aspirin and sodium salicylate through blockade of NF- κ B activation," <i>Science</i> , 274:1383-1385 (1996).	
		Hagihara et al., "Widespread gene transfection into the central nervous system of primates," <i>Gene Therapy</i> , 7:759-763 (2000).	
		Horikawa et al., "Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma," <i>Cancer</i> , 89:715-723 (2000).	
		Howard et al., "NF- κ B is activated and ICAM-1 gene expression is upregulated during reoxygenation of human brain endothelial cells," <i>Neuroscience Letters</i> , 248:199-203 (1998).	
		Ikeda et al., "Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography," <i>Clinical Cancer Research</i> , 6:3290-3296 (2000).	
		Jia et al., "Suppression of human microvascular endothelial cell invasion and morphogenesis with synthetic matrixin inhibitors. Targeting angiogenesis with MMP inhibitors," <i>Advances in Experimental Medicine and Biology</i> , 476: 181-194 (2002).	
		Jonas, "Hypothermia, circulatory arrest, and the pediatric brain," <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 10:66-74 (1996).	
		Kanda et al., "The role of the activated form of matrix metalloproteinase-2 in urothelial cancer," <i>BJU International</i> , 86:553-557 (2000)	
		Kim et al., "Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF- κ B-dependent pathway," <i>Biochemical and Biophysical Research Communications</i> , 269:401-405 (2000).	
		Kirino, "Delayed neuronal death in the gerbil hippocampus following ischemia," <i>Brain Research</i> , 239:57-69 (1982).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.




Substitute for form 1449/PTO		Complete if known	
		Application Number	10/509,799
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 15, 2005
		First Named Inventor	Yoshiki Sawa et al.
(use as many sheets as necessary)		Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet	4	of	7
		Attorney Docket Number	ANGES-5

NON PATENT LITERATURE DOCUMENTS			
		Kirklin et al., "The damaging effects of total circulatory arrest during hypothermia," <i>Cardiac Surgery</i> , 1:66-73 (1993).	
		Kuner et al., "β-amyloid binds to p75NTR and activates NFκB in human neuroblastoma cells," <i>Journal of Neuroscience Research</i> , 54:798-804 (1998).	
		Kurth et al., "Regional patterns of neuronal death after deep hypothermic circulatory arrest in newborn pigs," <i>Journal of Thoracic Cardiovascular Surgery</i> , 118:1068-1077 (1999).	
		La Rosa et al., "Differential regulation of the c-myc oncogene promoter by the NF-κB rel family of transcription factors," <i>Molecular and Cellular Biology</i> , 14(2):1039-1044 (1994).	
		Lenardo et al., "NF-κB: A pleiotropic mediator of inducible and tissue-specific gene control," <i>Cell</i> , 58:227-229 (1989).	
		Libermann et al., "Activation of interleukin-6 gene expression through NF-κB transcription factor," <i>Molecular and Cellular Biology</i> , 10(5):2327-2334 (1990).	
		Lin et al., "Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade," <i>Biochemical Pharmacology</i> , 58:911-915 (1999).	
		Mann et al., "Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial," <i>Lancet</i> , 354:1493-1498 (1999).	
		Marti HP, "New strategy to treat glomerular inflammation by inhibition of mesangial cell matrix metalloproteinases," <i>Schweiz Med Wochenschr</i> , 130(21): 784-788 (2000).	
		Morishita et al., "A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo," <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 92:5855-5859 (1995).	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.




Substitute for form 1449/PTO		Complete if known	
		Application Number	10/509,799
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 15, 2005
		First Named Inventor	Yoshiki Sawa et al.
		Art Unit	1614
		Examiner Name	Not Yet Assigned
(use as many sheets as necessary)		Attorney Docket Number	ANGES-5
Sheet	5	of	7

NON PATENT LITERATURE DOCUMENTS			
		Morishita et al., "Novel strategy of gene therapy in cardiovascular disease with HVJ-liposome method," <i>Progression of Chronic Renal Diseases, Contributions to Nephrology</i> , 118:254-264 (1996).	
		Morishita et al., "In vivo transfection of cis element "decoy" against nuclear factor- κ B binding site prevents myocardial infarction," <i>Nature Medicine</i> , 3(8):894-899 (1997).	
		Neish et al., "Function analysis of the human vascular cell adhesion molecule 1 promoter," <i>Journal of Experimental Medicine</i> , 176:1583-1593 (1992).	
		Ono et al., "Decoy administration of NF-kappaB into the subarachnoid space for cerebral angiopathy," <i>Human Gene Therapy</i> , 9(7):1003-1011 (1998). Erratum in: <i>Human Gene Therapy</i> 10(2):335 (1999).	
		Pellegrini et al., "Simultaneous measurement of soluble carcinoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer," <i>Cancer Immunology Immunotherapy</i> , 49:388-394 (2000).	
		Peters et al., "Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm," <i>Stroke</i> , 30:2612-2616 (1999).	
		Preston et al., "Evidence for pore-like opening of the blood-brain barrier following forebrain ischemia in rats," <i>Brain Research</i> , 761:4-10 (1997)	
		Rappaport et al., "Relation of seizures after cardiac surgery in early infancy to neurodevelopmental outcome," <i>Circulation</i> , 97:773-779 (1998).	
		Rayet et al., "Aberrant rel/nfkb genes and activity in human cancer," <i>Oncogene</i> , 18:6938-6947 (1999).	
		Reich et al., "Cardiopulmonary support and physiology," <i>Journal of Thoracic and Cardiovascular Surgery</i> , 117:156-163 (1999).	
		Royds et al., "Response of tumour cells to hypoxia: Role of p53 and NFkB," <i>Journal of Clinical Pathology: Molecular Pathology</i> , 51:55-61 (1998).	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known		
				Application Number	10/509,799	
Sheet		6	of	7	Filing Date	July 15, 2005
					First Named Inventor	Yoshiki Sawa et al.
					Art Unit	1614
					Examiner Name	Not Yet Assigned
					Attorney Docket Number	ANGES-5

NON PATENT LITERATURE DOCUMENTS			
		Sakata et al., "Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary," <i>International Journal of Oncology</i> , 17:673-681 (2000).	
		Satriano et al., "Activation and attenuation of transcription factor NF- κ B in mouse glomerular mesangial cells in response to tumor necrosis factor- α , immunoglobulin G, and adenosine 3':5'-cyclic monophosphate," <i>Journal of Clinical Investigation</i> , 94:1629-1636 (1994).	
		Sawa et al., "A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NF κ B binding site," <i>Circulation</i> , 96(9):II-280-285 (1997).	
		Schneider et al., "NF- κ B is activated and promotes cell death in focal cerebral ischemia," <i>Nature Medicine</i> , 5(5):554-559 (1999).	
		Schreck et al., "Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF- κ B transcription factor and HIV-1," <i>The EMBO Journal</i> , 10(8):2247-2258 (1991).	
		Schulze-Osthoff et al., "Regulation of NF- κ B activation by MAP kinase cascades," <i>Immunobiology</i> , 198:35-49 (1997).	
		Shin et al., "Effects of tumor necrosis factor- α and interferon- γ on expression of matrix metalloproteinase-2 and -9 in human bladder cancer cells," <i>Cancer Letters</i> , 159:127-134 (2000).	
		Stephenson et al., "Transcription factor nuclear factor-kappa B is activated in neurons after focal cerebral ischemia," <i>Journal of Cerebral Blood Flow and Metabolism</i> , 20:592-603 (2000).	
		Sullenger et al., "Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation," <i>Journal of Virology</i> , 65(12):6811-6816 (1991).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449/PTO		Complete if known			
		Application Number	10/509,799		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	July 15, 2005		
		First Named Inventor	Yoshiki Sawa et al.		
		Art Unit	1614		
		Examiner Name	Not Yet Assigned		
Sheet	7	of	7	Attorney Docket Number	ANGES-5

NON PATENT LITERATURE DOCUMENTS			
		Szoka et al., "Preparation of unilamellar liposomes of intermediate size (0.1-0.2 μ m) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes," <i>Biochimica et Biophysica Acta</i> , 601:559-571 (1980).	
		Tomita et al., "Transcription factor decoy for NF κ B inhibits TNF- α -induced cytokine and adhesion molecule expression in vivo," <i>Gene Therapy</i> , 7:1326-1332 (2000).	
		Tomita et al., "Transcription factor decoy for NF κ B inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis," <i>Rheumatology</i> , 39:749-757 (2000).	
		Torre et al., "Partial or global rat brain ischemia: the SCOT model," <i>Brain Research Bulletin</i> , 26:365-372 (1991).	
		Treharne et al., "Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease," <i>British Journal of Surgery</i> , 86:1053-1058 (1999).	
		Turner et al., "Role of matrix metalloproteinase 9 in pituitary tumor behavior," <i>Journal of Clinical Endocrinology & Metabolism</i> , 85(8):2931-2935 (2000).	
		Vanicky et al., "Alterations in MAP2 immunostainability after prolonged complete brain ischemia in the rat," <i>NeuroReport</i> , 7:161-164 (1995).	
		Vogt et al., "Oxidative stress and hypoxia/reoxygenation trigger CD95 (APO-1/Fas) ligand expression in microglial cells," <i>FEBS Letters</i> , 429:67-72 (1998).	
		Wu et al., "NF- κ B activation of p53," <i>Journal of Biological Chemistry</i> , 269(31):20067-20074 (1994).	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and-or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.